Diagnostic kits for cancer detection from XEPTAGEN SpA

XEPTAGEN SpA (XEPTAGEN) is a medical device company based in Italy. The company discovers novel molecular markers to produce diagnostic kits for the early detection, monitoring, and screening of cancerous cells.

Their product portofolio include diagnostic kits to detect liver cancer, colorectal cancer, prostate cancer and squamous cell carcinomas (i.e. all cancers that affect the squamous epithelial cell layer).

XEPTAGEN uses the Combinatorial Proteomic® technology to discover specific tumor markers. Combinatorial Proteomic® is the high-throughput analysis of protein expression and function. The identification of proteins uniquely expressed in specific cancers would enable an earlier and accurate detection of developing carcinomas.